Welcome to our dedicated page for Impact Biomedical news (Ticker: IBO), a resource for investors and traders seeking the latest updates and insights on Impact Biomedical stock.
Impact BioMedical Inc. (NYSE American: IBO) is a biotechnology company that focuses on discovering, confirming, and patenting unique science and technologies for human healthcare and wellness. Its news flow reflects this intellectual property–driven model, highlighting developments across platforms such as Linebacker™, Equivir™, Laetose™, and 3F™, as well as corporate transactions and capital markets activity.
News updates often cover patent issuances and IP milestones. For example, the company has announced U.S. and Canadian patents for its Linebacker™ platform targeting inflammatory-related diseases, and U.S. patents within its 3F™ technology platform for insect repelling compositions and functional fragrances aimed at controlling infectious diseases. These announcements describe the scientific focus of each platform and the potential application areas the company is pursuing.
Investors and followers of IBO can also expect corporate and strategic news, including the company’s initial public offering on the NYSE American, shareholder letters outlining strategic vision and platform progress, and updates on acquisitions such as the all-equity purchase of Celios®, an air purification technology company with patented systems designed to deliver high-level indoor air quality.
A significant portion of Impact BioMedical’s recent news relates to merger and transaction activity. The company has disclosed a Merger and Share Exchange Agreement with Dr Ashleys entities and a newly formed PubCo, under which Impact BioMedical and Dr Ashleys are expected to become wholly owned subsidiaries of PubCo, with the combined entity trading on NYSE American under the name “Dr Ashleys Limited,” subject to approvals and closing conditions.
Additional news items include participation in investor conferences, commentary on stock trading activity, and introductions of the executive leadership team. For ongoing coverage of IBO, this news page aggregates company press releases and related announcements so readers can follow patent progress, partnership developments, transaction milestones, and other key corporate events.
Impact Biomedical (IBO) has secured U.S. patent No. 12,357,584 B2 for its 3F™ technology platform, focusing on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
The technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77%. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
Impact BioMedical (NYSE American: IBO) released a statement on March 21, 2025, addressing unusual market activity in its stock price. The company confirmed that there have been no material developments in its business operations beyond what has been previously disclosed to the public. The biotechnology company, which focuses on discovering, developing, and patenting innovative healthcare solutions, stated it is unaware of any other reasons that could explain the unusual trading activity in its shares.
Impact BioMedical Inc. (NYSE American: IBO) has announced the acquisition of Celios®, an air purification technology company, in an all-equity transaction valued at $1.15 million. The strategic acquisition expands IBO's portfolio with patented air purification technology that delivers virtually clean room air quality.
Celios® brings design, system, and method patents with exclusivity through 2043, featuring U.S. manufactured filter technology that is both highly effective and portable. The acquisition aligns with Impact BioMedical's roll-up strategy, aiming to generate immediate revenue while maintaining their current cash position.
Impact BioMedical Inc. (NYSE American: IBO) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO Frank D. Heuszel will deliver a corporate presentation on Wednesday, January 29, 2025, at 10:30 AM ET.
During the conference, Heuszel will conduct one-on-one meetings with investors to discuss the company's recent developments, growth strategy, and investment opportunities. Impact BioMedical, a biotechnology company, focuses on discovering, confirming, and patenting unique science and technologies for development into biopharmaceuticals and consumer healthcare solutions through various collaborative relationships including research, licensing, co-development, and joint ventures.
Impact BioMedical (NYSE American: IBO) released a shareholder letter highlighting its Q3 2024 achievements. The company completed its IPO in September 2024, raising $4.5 million through 1.5 million freely tradable shares. Q3 2024 reported net income of $4,241,000, with year-to-date net income at $2,363,000. Shareholder equity increased by $6.3 million to $34.56 million. The company has strategic partnerships with ProPhase Labs for Equivir™ and Linebacker™ development, while Laetose™ and 3F™ platforms are available for partnering. A debt restructuring allows repayment with company equity over 24 months.
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory diseases.
The Linebacker™ technology targets key inflammatory pathways, potentially reducing inflammation and providing symptomatic relief with fewer side effects compared to traditional anti-inflammatory medications. The patent includes a method for using Linebacker™ formulations to inhibit inflammatory responses in conditions such as arthritis, asthma, and inflammatory bowel disease.
This is the first Linebacker™ patent issued in Canada, with an expiration date in May 2037. CEO Frank D. Heuszel highlighted the significance of this achievement, noting that the Canadian Inflammatory Disease Treatment Market was estimated at $7B in 2022.
Impact BioMedical Inc. (NYSE American: IBO) has successfully completed its Initial Public Offering (IPO). The biotechnology company, focused on discovering, developing, and patenting innovative healthcare solutions, saw strong support from existing investors, who purchased over 30% of the IPO shares. This significant participation demonstrates confidence in the company's mission and potential.
Frank D. Heuszel, CEO of Impact BioMedical, expressed that the substantial involvement of existing investors underscores their belief in the company's work and its potential to make a meaningful impact on human health. The successful IPO marks an important milestone for Impact BioMedical as it continues its efforts in developing innovative healthcare solutions.
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of U.S. Patent No. 11,985,973 for its 3F™ technology platform, titled 'Insect Repelling Composition'. This patent, along with the previously granted U.S. Patent No. 11,246,310, covers natural insect repellent compositions derived from plant constituents and fragrances. These patents will expire in February 2039 and April 2040, respectively.
The 3F™ technology inhibits insect olfactory receptors, effectively 'blinding' insects to human presence. Potential applications include mosquito repellents and additives for detergents, shampoos, or lotions. This innovation addresses the global issue of vector-borne diseases, which account for 17% of all infectious diseases worldwide according to the WHO.
IBO CEO Frank D. Heuszel stated that this patent issuance demonstrates the company's successful business model in delivering unique proprietary technology for unmet healthcare needs. IBO is now accelerating discussions with potential partners to bring 3F™ to market in the US and globally.
Impact BioMedical Inc. (NYSE American: IBO) has unveiled its executive leadership team to spearhead the company's next phase of innovation and growth. The team includes:
Frank D. Heuszel as CEO, bringing experience in executive leadership, finance, and strategic planning. He previously served as CEO of DSS, Inc. and has a background in commercial banking.
Mark Suseck as COO, with experience in public and private healthcare companies. He previously served as COO of DSS BioHealth Holdings Inc. and CEO of Vivacitas Oncology Inc.
Todd Macko as CFO, also serving as CFO of DSS Inc. He brings over 25 years of public and corporate fiscal management experience.
The leadership team aims to advance Impact BioMedical's mission of discovering, developing, and patenting unique healthcare solutions.